Century Therapeutics, Inc. Business Combination, Contingent Consideration, Liability, Current
Century Therapeutics, Inc. (IPSC) had Business Combination, Contingent Consideration, Liability, Current of $1.94 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-08-12
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Current $1.94M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $3.76M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $8.34M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2026-03-31 | $1.94M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.76M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $8.34M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |